Aspen Neuroscience (NASDAQ:ASPE) Major Shareholder Purchases $1,999,995.00 in Stock

Aspen Neuroscience, Inc. (NASDAQ:ASPE) major shareholder Venture Fund L.P. Arch bought 133,333 shares of the firm’s stock in a transaction that occurred on Monday, November 2nd. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $1,999,995.00. Following the purchase, the insider owned 66,667 shares in the company, valued at $1,000,005. This represents a -200.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Aspen Neuroscience Price Performance

Shares of Aspen Neuroscience stock opened at $11.76 on Friday. Aspen Neuroscience, Inc. has a 12 month low of $11.20 and a 12 month high of $14.90.

Aspen Neuroscience Company Profile

Aspen Neuroscience, Inc is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company’s approach uses a patient’s own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue.

Aspen’s lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson’s disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient’s cells and produce an individualized therapeutic product.

Aspen Neuroscience is headquartered in San Diego, California.